-onium
Drugs with a permanently charged nitrogen (quaternary ammonium), like many muscle relaxants.
- Drugs ending in -onium: 35
- Approved somewhere: 5
- With a US drug page: 12
- Stem
- -onium
- Class
- Drugs with a permanently charged nitrogen (quaternary ammonium), like many muscle relaxants
- Sub-stem of
- -ium: Drugs with a permanently charged nitrogen (quaternary ammonium)
- Most common targets
- Muscle-type nicotinic acetylcholine receptor (7), CHRM3 (2), CHRM1 (2), Muscarinic acetylcholine receptor (2), ACHE (2), Lanosterol 14-alpha demethylase (1), Cell membrane (1), CHRM2 (1)
Approved and clinical-stage drugs in ChEMBL whose names ending in -onium, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Glycopyrronium | Approved | CHRM3, CHRM1, Muscarinic acetylcholine receptor | Muscarinic acetylcholine receptor M3 antagonist |
| Isavuconazonium | Approved | Lanosterol 14-alpha demethylase | Lanosterol 14-alpha demethylase inhibitor |
| Oxyphenonium | Approved | CHRM3, CHRM1 | Muscarinic acetylcholine receptor M3 antagonist |
| Sofpironium | Approved | Muscarinic acetylcholine receptor | Muscarinic acetylcholine receptor inhibitor |
| Rocuronium | Phase 3 | Muscle-type nicotinic acetylcholine receptor | Muscle-type nicotinic acetylcholine receptor antagonist |
| Edrophonium | Phase 1 | ACHE | Acetylcholinesterase inhibitor |
| Ambenonium | — | ACHE | Acetylcholinesterase inhibitor |
| Decamethonium | — | Muscle-type nicotinic acetylcholine receptor | Muscle-type nicotinic acetylcholine receptor partial agonist |
| Pancuronium | — | Muscle-type nicotinic acetylcholine receptor | Muscle-type nicotinic acetylcholine receptor antagonist |
| Pipecuronium | — | Muscle-type nicotinic acetylcholine receptor | Muscle-type nicotinic acetylcholine receptor antagonist |
| Rapacuronium | — | Muscle-type nicotinic acetylcholine receptor | Muscle-type nicotinic acetylcholine receptor antagonist |
| Vecuronium | — | Muscle-type nicotinic acetylcholine receptor | Muscle-type nicotinic acetylcholine receptor antagonist |
| Emepronium | Approved | — | — |
| Diammonium glycyrrhizinate | Phase 3 | — | — |
| Otilonium | Phase 3 | — | — |
| Suxamethonium | Phase 3 | Muscle-type nicotinic acetylcholine receptor | Muscle-type nicotinic acetylcholine receptor agonist |
| Benzoxonium | Phase 2 | — | — |
| Bibenzonium | Phase 2 | — | — |
| Denatonium | Phase 2 | — | — |
| Meldonium | Phase 2 | — | — |
| Sepantronium | Phase 2 | — | — |
| Tibezonium | Phase 2 | — | — |
| Tiemonium | Phase 2 | — | — |
| Zirconium (89ZR) girentuximab senvedoxam | Phase 2 | — | — |
| Ammonium tetrathiomolybdate | Phase 1 | — | — |
| Benzalkonium | Phase 1 | Cell membrane | Cell membrane disrupting agent |
| Tolonium | Phase 1 | — | — |
| Zirconium ZR-89-desferrioxamine-IAB22M2C | Phase 1 | — | — |
| Alcuronium | — | CHRM2 | Muscarinic acetylcholine receptor M2 positive allosteric modulator |
| Ambutonium | — | — | Unknown |
| Ammonium lactate | — | — | Unknown |
| Benzilonium | — | — | — |
| Bevonium | — | — | — |
| Fentonium | — | — | — |
| Methiosulfonium | — | — | — |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO